nodes	percent_of_prediction	percent_of_DWPC	metapath
Trihexyphenidyl—Cognitive impairment—Delavirdine—acquired immunodeficiency syndrome	0.0429	0.0495	CcSEcCtD
Trihexyphenidyl—Urinary hesitation—Zidovudine—acquired immunodeficiency syndrome	0.0324	0.0374	CcSEcCtD
Trihexyphenidyl—Cognitive disorder—Delavirdine—acquired immunodeficiency syndrome	0.0259	0.0298	CcSEcCtD
Trihexyphenidyl—Urinary hesitation—Lamivudine—acquired immunodeficiency syndrome	0.0232	0.0267	CcSEcCtD
Trihexyphenidyl—Accommodation disorder—Indinavir—acquired immunodeficiency syndrome	0.0215	0.0249	CcSEcCtD
Trihexyphenidyl—Paranoia—Efavirenz—acquired immunodeficiency syndrome	0.0172	0.0198	CcSEcCtD
Trihexyphenidyl—Delusion—Efavirenz—acquired immunodeficiency syndrome	0.0165	0.0191	CcSEcCtD
Trihexyphenidyl—Hyperkinesia—Nelfinavir—acquired immunodeficiency syndrome	0.0134	0.0155	CcSEcCtD
Trihexyphenidyl—Dry skin—Stavudine—acquired immunodeficiency syndrome	0.0102	0.0118	CcSEcCtD
Trihexyphenidyl—Euphoric mood—Efavirenz—acquired immunodeficiency syndrome	0.01	0.0116	CcSEcCtD
Trihexyphenidyl—Euphoric mood—Delavirdine—acquired immunodeficiency syndrome	0.00961	0.0111	CcSEcCtD
Trihexyphenidyl—Hyperkinesia—Ritonavir—acquired immunodeficiency syndrome	0.00902	0.0104	CcSEcCtD
Trihexyphenidyl—Euphoric mood—Ritonavir—acquired immunodeficiency syndrome	0.00889	0.0103	CcSEcCtD
Trihexyphenidyl—Weight decreased—Stavudine—acquired immunodeficiency syndrome	0.00869	0.01	CcSEcCtD
Trihexyphenidyl—Euphoric mood—Saquinavir—acquired immunodeficiency syndrome	0.00856	0.00987	CcSEcCtD
Trihexyphenidyl—Psychotic disorder—Efavirenz—acquired immunodeficiency syndrome	0.00829	0.00956	CcSEcCtD
Trihexyphenidyl—Dry skin—Indinavir—acquired immunodeficiency syndrome	0.00823	0.0095	CcSEcCtD
Trihexyphenidyl—Weight decreased—Zidovudine—acquired immunodeficiency syndrome	0.00755	0.00871	CcSEcCtD
Trihexyphenidyl—Dry skin—Delavirdine—acquired immunodeficiency syndrome	0.00744	0.00859	CcSEcCtD
Trihexyphenidyl—Psychotic disorder—Saquinavir—acquired immunodeficiency syndrome	0.00706	0.00815	CcSEcCtD
Trihexyphenidyl—Dry skin—Ritonavir—acquired immunodeficiency syndrome	0.00688	0.00794	CcSEcCtD
Trihexyphenidyl—Dry skin—Saquinavir—acquired immunodeficiency syndrome	0.00663	0.00764	CcSEcCtD
Trihexyphenidyl—Drowsiness—Efavirenz—acquired immunodeficiency syndrome	0.00654	0.00755	CcSEcCtD
Trihexyphenidyl—Agitation—Nelfinavir—acquired immunodeficiency syndrome	0.00617	0.00712	CcSEcCtD
Trihexyphenidyl—Weight decreased—Ritonavir—acquired immunodeficiency syndrome	0.00587	0.00678	CcSEcCtD
Trihexyphenidyl—Hallucination—Efavirenz—acquired immunodeficiency syndrome	0.00584	0.00674	CcSEcCtD
Trihexyphenidyl—Tension—Zidovudine—acquired immunodeficiency syndrome	0.00571	0.00659	CcSEcCtD
Trihexyphenidyl—Weight decreased—Saquinavir—acquired immunodeficiency syndrome	0.00565	0.00652	CcSEcCtD
Trihexyphenidyl—Nervousness—Zidovudine—acquired immunodeficiency syndrome	0.00565	0.00652	CcSEcCtD
Trihexyphenidyl—Hallucination—Delavirdine—acquired immunodeficiency syndrome	0.00559	0.00645	CcSEcCtD
Trihexyphenidyl—Tension—Indinavir—acquired immunodeficiency syndrome	0.00531	0.00613	CcSEcCtD
Trihexyphenidyl—Nervousness—Indinavir—acquired immunodeficiency syndrome	0.00525	0.00606	CcSEcCtD
Trihexyphenidyl—Hallucination—Ritonavir—acquired immunodeficiency syndrome	0.00517	0.00596	CcSEcCtD
Trihexyphenidyl—Vision blurred—Indinavir—acquired immunodeficiency syndrome	0.0051	0.00588	CcSEcCtD
Trihexyphenidyl—Somnolence—Nevirapine—acquired immunodeficiency syndrome	0.00503	0.0058	CcSEcCtD
Trihexyphenidyl—Tension—Efavirenz—acquired immunodeficiency syndrome	0.00502	0.00579	CcSEcCtD
Trihexyphenidyl—Hallucination—Saquinavir—acquired immunodeficiency syndrome	0.00498	0.00574	CcSEcCtD
Trihexyphenidyl—Agitation—Indinavir—acquired immunodeficiency syndrome	0.00497	0.00574	CcSEcCtD
Trihexyphenidyl—Nervousness—Efavirenz—acquired immunodeficiency syndrome	0.00496	0.00573	CcSEcCtD
Trihexyphenidyl—Asthenia—Amprenavir—acquired immunodeficiency syndrome	0.00495	0.00571	CcSEcCtD
Trihexyphenidyl—Somnolence—Nelfinavir—acquired immunodeficiency syndrome	0.00487	0.00562	CcSEcCtD
Trihexyphenidyl—Somnolence—Stavudine—acquired immunodeficiency syndrome	0.00486	0.0056	CcSEcCtD
Trihexyphenidyl—Vision blurred—Efavirenz—acquired immunodeficiency syndrome	0.00482	0.00556	CcSEcCtD
Trihexyphenidyl—Tension—Delavirdine—acquired immunodeficiency syndrome	0.0048	0.00554	CcSEcCtD
Trihexyphenidyl—Confusional state—Zidovudine—acquired immunodeficiency syndrome	0.00479	0.00552	CcSEcCtD
Trihexyphenidyl—Nervousness—Delavirdine—acquired immunodeficiency syndrome	0.00475	0.00548	CcSEcCtD
Trihexyphenidyl—Agitation—Efavirenz—acquired immunodeficiency syndrome	0.0047	0.00542	CcSEcCtD
Trihexyphenidyl—Constipation—Stavudine—acquired immunodeficiency syndrome	0.00467	0.00539	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Nevirapine—acquired immunodeficiency syndrome	0.00466	0.00538	CcSEcCtD
Trihexyphenidyl—Vision blurred—Delavirdine—acquired immunodeficiency syndrome	0.00461	0.00532	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Nelfinavir—acquired immunodeficiency syndrome	0.00452	0.00521	CcSEcCtD
Trihexyphenidyl—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.00451	0.00521	CcSEcCtD
Trihexyphenidyl—Agitation—Delavirdine—acquired immunodeficiency syndrome	0.00449	0.00519	CcSEcCtD
Trihexyphenidyl—Tension—Ritonavir—acquired immunodeficiency syndrome	0.00444	0.00512	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Abacavir—acquired immunodeficiency syndrome	0.00443	0.00512	CcSEcCtD
Trihexyphenidyl—Nervousness—Ritonavir—acquired immunodeficiency syndrome	0.00439	0.00507	CcSEcCtD
Trihexyphenidyl—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.00439	0.00506	CcSEcCtD
Trihexyphenidyl—Rash—Amprenavir—acquired immunodeficiency syndrome	0.00435	0.00502	CcSEcCtD
Trihexyphenidyl—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.00435	0.00502	CcSEcCtD
Trihexyphenidyl—Headache—Amprenavir—acquired immunodeficiency syndrome	0.00432	0.00499	CcSEcCtD
Trihexyphenidyl—Vision blurred—Ritonavir—acquired immunodeficiency syndrome	0.00426	0.00492	CcSEcCtD
Trihexyphenidyl—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.00422	0.00487	CcSEcCtD
Trihexyphenidyl—Confusional state—Efavirenz—acquired immunodeficiency syndrome	0.00421	0.00485	CcSEcCtD
Trihexyphenidyl—Agitation—Ritonavir—acquired immunodeficiency syndrome	0.00416	0.0048	CcSEcCtD
Trihexyphenidyl—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.0041	0.00473	CcSEcCtD
Trihexyphenidyl—Tension—Lamivudine—acquired immunodeficiency syndrome	0.00408	0.0047	CcSEcCtD
Trihexyphenidyl—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.00407	0.0047	CcSEcCtD
Trihexyphenidyl—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.00406	0.00468	CcSEcCtD
Trihexyphenidyl—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.00406	0.00468	CcSEcCtD
Trihexyphenidyl—Nervousness—Lamivudine—acquired immunodeficiency syndrome	0.00403	0.00465	CcSEcCtD
Trihexyphenidyl—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.00402	0.00464	CcSEcCtD
Trihexyphenidyl—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.004	0.00462	CcSEcCtD
Trihexyphenidyl—Agitation—Saquinavir—acquired immunodeficiency syndrome	0.004	0.00462	CcSEcCtD
Trihexyphenidyl—Rash—Didanosine—acquired immunodeficiency syndrome	0.00397	0.00458	CcSEcCtD
Trihexyphenidyl—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.00396	0.00457	CcSEcCtD
Trihexyphenidyl—Headache—Didanosine—acquired immunodeficiency syndrome	0.00394	0.00455	CcSEcCtD
Trihexyphenidyl—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.00393	0.00454	CcSEcCtD
Trihexyphenidyl—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.00393	0.00453	CcSEcCtD
Trihexyphenidyl—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.00392	0.00452	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.00391	0.00451	CcSEcCtD
Trihexyphenidyl—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.0039	0.00449	CcSEcCtD
Trihexyphenidyl—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.00386	0.00445	CcSEcCtD
Trihexyphenidyl—Constipation—Indinavir—acquired immunodeficiency syndrome	0.00378	0.00436	CcSEcCtD
Trihexyphenidyl—Nausea—Didanosine—acquired immunodeficiency syndrome	0.00374	0.00431	CcSEcCtD
Trihexyphenidyl—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.00372	0.00429	CcSEcCtD
Trihexyphenidyl—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.00371	0.00428	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.00364	0.0042	CcSEcCtD
Trihexyphenidyl—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.00362	0.00418	CcSEcCtD
Trihexyphenidyl—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.00361	0.00417	CcSEcCtD
Trihexyphenidyl—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.0036	0.00416	CcSEcCtD
Trihexyphenidyl—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.0036	0.00415	CcSEcCtD
Trihexyphenidyl—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.00358	0.00413	CcSEcCtD
Trihexyphenidyl—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.00357	0.00412	CcSEcCtD
Trihexyphenidyl—Rash—Nevirapine—acquired immunodeficiency syndrome	0.00357	0.00412	CcSEcCtD
Trihexyphenidyl—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.00356	0.00411	CcSEcCtD
Trihexyphenidyl—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.00356	0.00411	CcSEcCtD
Trihexyphenidyl—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.00355	0.00409	CcSEcCtD
Trihexyphenidyl—Headache—Nevirapine—acquired immunodeficiency syndrome	0.00354	0.00409	CcSEcCtD
Trihexyphenidyl—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.00348	0.00402	CcSEcCtD
Trihexyphenidyl—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.00347	0.00401	CcSEcCtD
Trihexyphenidyl—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.00345	0.00399	CcSEcCtD
Trihexyphenidyl—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.00345	0.00398	CcSEcCtD
Trihexyphenidyl—Rash—Stavudine—acquired immunodeficiency syndrome	0.00344	0.00397	CcSEcCtD
Trihexyphenidyl—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.00344	0.00397	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.00344	0.00397	CcSEcCtD
Trihexyphenidyl—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.00343	0.00396	CcSEcCtD
Trihexyphenidyl—Headache—Stavudine—acquired immunodeficiency syndrome	0.00342	0.00395	CcSEcCtD
Trihexyphenidyl—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.00342	0.00395	CcSEcCtD
Trihexyphenidyl—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.00342	0.00394	CcSEcCtD
Trihexyphenidyl—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.00341	0.00394	CcSEcCtD
Trihexyphenidyl—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.00341	0.00393	CcSEcCtD
Trihexyphenidyl—Rash—Abacavir—acquired immunodeficiency syndrome	0.00339	0.00391	CcSEcCtD
Trihexyphenidyl—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.00339	0.00391	CcSEcCtD
Trihexyphenidyl—Headache—Abacavir—acquired immunodeficiency syndrome	0.00337	0.00389	CcSEcCtD
Trihexyphenidyl—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.00336	0.00388	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.00329	0.0038	CcSEcCtD
Trihexyphenidyl—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.00328	0.00379	CcSEcCtD
Trihexyphenidyl—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.00325	0.00376	CcSEcCtD
Trihexyphenidyl—Nausea—Stavudine—acquired immunodeficiency syndrome	0.00324	0.00374	CcSEcCtD
Trihexyphenidyl—Nausea—Abacavir—acquired immunodeficiency syndrome	0.0032	0.00369	CcSEcCtD
Trihexyphenidyl—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.00317	0.00366	CcSEcCtD
Trihexyphenidyl—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.00316	0.00364	CcSEcCtD
Trihexyphenidyl—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.00316	0.00364	CcSEcCtD
Trihexyphenidyl—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.00314	0.00362	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.00304	0.00351	CcSEcCtD
Trihexyphenidyl—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.00304	0.00351	CcSEcCtD
Trihexyphenidyl—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.00302	0.00348	CcSEcCtD
Trihexyphenidyl—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.00301	0.00348	CcSEcCtD
Trihexyphenidyl—Rash—Zidovudine—acquired immunodeficiency syndrome	0.00299	0.00345	CcSEcCtD
Trihexyphenidyl—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.00299	0.00345	CcSEcCtD
Trihexyphenidyl—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.00299	0.00345	CcSEcCtD
Trihexyphenidyl—Headache—Zidovudine—acquired immunodeficiency syndrome	0.00297	0.00343	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.00293	0.00338	CcSEcCtD
Trihexyphenidyl—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.00292	0.00337	CcSEcCtD
Trihexyphenidyl—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.0029	0.00334	CcSEcCtD
Trihexyphenidyl—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.00286	0.0033	CcSEcCtD
Trihexyphenidyl—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.00282	0.00325	CcSEcCtD
Trihexyphenidyl—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.00281	0.00324	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.00279	0.00322	CcSEcCtD
Trihexyphenidyl—Rash—Indinavir—acquired immunodeficiency syndrome	0.00278	0.00321	CcSEcCtD
Trihexyphenidyl—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.00278	0.00321	CcSEcCtD
Trihexyphenidyl—Headache—Indinavir—acquired immunodeficiency syndrome	0.00277	0.00319	CcSEcCtD
Trihexyphenidyl—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.00276	0.00318	CcSEcCtD
Trihexyphenidyl—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.00265	0.00306	CcSEcCtD
Trihexyphenidyl—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.00265	0.00306	CcSEcCtD
Trihexyphenidyl—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.00264	0.00305	CcSEcCtD
Trihexyphenidyl—Rash—Efavirenz—acquired immunodeficiency syndrome	0.00263	0.00303	CcSEcCtD
Trihexyphenidyl—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.00263	0.00303	CcSEcCtD
Trihexyphenidyl—Nausea—Indinavir—acquired immunodeficiency syndrome	0.00262	0.00303	CcSEcCtD
Trihexyphenidyl—Headache—Efavirenz—acquired immunodeficiency syndrome	0.00261	0.00302	CcSEcCtD
Trihexyphenidyl—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.00255	0.00294	CcSEcCtD
Trihexyphenidyl—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.00254	0.00293	CcSEcCtD
Trihexyphenidyl—Rash—Delavirdine—acquired immunodeficiency syndrome	0.00252	0.0029	CcSEcCtD
Trihexyphenidyl—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.00251	0.0029	CcSEcCtD
Trihexyphenidyl—Headache—Delavirdine—acquired immunodeficiency syndrome	0.0025	0.00289	CcSEcCtD
Trihexyphenidyl—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.00248	0.00286	CcSEcCtD
Trihexyphenidyl—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.00244	0.00282	CcSEcCtD
Trihexyphenidyl—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.00243	0.00281	CcSEcCtD
Trihexyphenidyl—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.00237	0.00274	CcSEcCtD
Trihexyphenidyl—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.00235	0.00271	CcSEcCtD
Trihexyphenidyl—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.00235	0.00271	CcSEcCtD
Trihexyphenidyl—Rash—Ritonavir—acquired immunodeficiency syndrome	0.00233	0.00269	CcSEcCtD
Trihexyphenidyl—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.00233	0.00268	CcSEcCtD
Trihexyphenidyl—Headache—Ritonavir—acquired immunodeficiency syndrome	0.00231	0.00267	CcSEcCtD
Trihexyphenidyl—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.00226	0.00261	CcSEcCtD
Trihexyphenidyl—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.00224	0.00259	CcSEcCtD
Trihexyphenidyl—Rash—Saquinavir—acquired immunodeficiency syndrome	0.00224	0.00258	CcSEcCtD
Trihexyphenidyl—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.00224	0.00258	CcSEcCtD
Trihexyphenidyl—Headache—Saquinavir—acquired immunodeficiency syndrome	0.00223	0.00257	CcSEcCtD
Trihexyphenidyl—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.00219	0.00253	CcSEcCtD
Trihexyphenidyl—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.00215	0.00249	CcSEcCtD
Trihexyphenidyl—Rash—Lamivudine—acquired immunodeficiency syndrome	0.00214	0.00247	CcSEcCtD
Trihexyphenidyl—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.00214	0.00246	CcSEcCtD
Trihexyphenidyl—Headache—Lamivudine—acquired immunodeficiency syndrome	0.00212	0.00245	CcSEcCtD
Trihexyphenidyl—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.00211	0.00243	CcSEcCtD
Trihexyphenidyl—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.00201	0.00232	CcSEcCtD
Trihexyphenidyl—CHRM4—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000747	0.0058	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000715	0.00555	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000702	0.00545	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000702	0.00545	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000687	0.00533	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000684	0.00531	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000678	0.00526	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000673	0.00522	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000673	0.00522	CbGpPWpGaD
Trihexyphenidyl—CHRM4—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000672	0.00522	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000629	0.00488	CbGpPWpGaD
Trihexyphenidyl—CHRM2—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000625	0.00485	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000621	0.00482	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000619	0.0048	CbGpPWpGaD
Trihexyphenidyl—CHRM2—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.000618	0.0048	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000613	0.00476	CbGpPWpGaD
Trihexyphenidyl—CHRM4—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000605	0.0047	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000602	0.00468	CbGpPWpGaD
Trihexyphenidyl—CHRM2—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000588	0.00456	CbGpPWpGaD
Trihexyphenidyl—CHRM2—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000588	0.00456	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000588	0.00456	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000586	0.00455	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000582	0.00451	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00058	0.0045	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00058	0.0045	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000574	0.00446	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000569	0.00442	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000562	0.00436	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000557	0.00432	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000555	0.00431	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000553	0.00429	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000551	0.00428	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.00055	0.00427	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000546	0.00424	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000545	0.00423	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000538	0.00418	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000535	0.00415	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000535	0.00415	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000534	0.00415	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000523	0.00406	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000512	0.00398	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000512	0.00398	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000512	0.00397	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000509	0.00395	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000504	0.00391	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000502	0.0039	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.0005	0.00388	CbGpPWpGaD
Trihexyphenidyl—CHRM5—skin of body—acquired immunodeficiency syndrome	0.000499	0.113	CbGeAlD
Trihexyphenidyl—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000497	0.00386	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000488	0.00379	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000481	0.00374	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000474	0.00368	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000474	0.00368	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000473	0.00367	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000472	0.00366	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000472	0.00366	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000468	0.00363	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000468	0.00363	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000461	0.00358	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000453	0.00351	CbGpPWpGaD
Trihexyphenidyl—CHRM2—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000447	0.00347	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000424	0.00329	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000423	0.00328	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000419	0.00325	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000407	0.00316	CbGpPWpGaD
Trihexyphenidyl—CHRM2—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000403	0.00313	CbGpPWpGaD
Trihexyphenidyl—CHRM4—nervous system—acquired immunodeficiency syndrome	0.000395	0.0893	CbGeAlD
Trihexyphenidyl—CHRM5—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.00039	0.00302	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000384	0.00298	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000382	0.00297	CbGpPWpGaD
Trihexyphenidyl—CHRM4—central nervous system—acquired immunodeficiency syndrome	0.00038	0.086	CbGeAlD
Trihexyphenidyl—CHRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000379	0.00294	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000379	0.00294	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000378	0.00293	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000374	0.0029	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000367	0.00285	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—TAT—acquired immunodeficiency syndrome	0.000365	0.00283	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000361	0.0028	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000361	0.0028	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00036	0.0028	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.00036	0.00279	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.00036	0.00279	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000359	0.00279	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000356	0.00276	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000356	0.00276	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000356	0.00276	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000352	0.00273	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000351	0.00273	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000351	0.00272	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000348	0.0027	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000344	0.00267	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000342	0.00266	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000339	0.00263	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000325	0.00252	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000324	0.00251	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000323	0.00251	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000322	0.0025	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.00032	0.00249	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000319	0.00247	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000318	0.00247	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000315	0.00244	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—AGPS—acquired immunodeficiency syndrome	0.00031	0.00241	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000309	0.0024	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000309	0.0024	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000309	0.0024	CbGpPWpGaD
Trihexyphenidyl—CHRM5—nervous system—acquired immunodeficiency syndrome	0.000308	0.0698	CbGeAlD
Trihexyphenidyl—CHRM5—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000308	0.00239	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000302	0.00235	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000302	0.00235	CbGpPWpGaD
Trihexyphenidyl—CHRM4—brain—acquired immunodeficiency syndrome	0.000302	0.0682	CbGeAlD
Trihexyphenidyl—CHRM5—central nervous system—acquired immunodeficiency syndrome	0.000297	0.0672	CbGeAlD
Trihexyphenidyl—CHRM5—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000296	0.00229	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000296	0.00229	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000292	0.00227	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000289	0.00225	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000289	0.00225	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.00028	0.00217	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000279	0.00217	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000274	0.00213	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000274	0.00213	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000274	0.00213	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000274	0.00212	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000271	0.0021	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000267	0.00207	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000263	0.00204	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000263	0.00204	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000247	0.00192	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000246	0.00191	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000244	0.00189	CbGpPWpGaD
Trihexyphenidyl—CHRM5—brain—acquired immunodeficiency syndrome	0.000236	0.0533	CbGeAlD
Trihexyphenidyl—CHRM2—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	0.000235	0.00183	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.00023	0.00178	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000227	0.00176	CbGpPWpGaD
Trihexyphenidyl—CHRM3—digestive system—acquired immunodeficiency syndrome	0.000223	0.0505	CbGeAlD
Trihexyphenidyl—CHRM5—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.00022	0.00171	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000218	0.00169	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000217	0.00168	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000217	0.00168	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000217	0.00168	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000216	0.00168	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000215	0.00167	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000214	0.00166	CbGpPWpGaD
Trihexyphenidyl—CHRM2—nervous system—acquired immunodeficiency syndrome	0.000212	0.0479	CbGeAlD
Trihexyphenidyl—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	0.000211	0.00164	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000209	0.00162	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000208	0.00162	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000208	0.00162	CbGpPWpGaD
Trihexyphenidyl—CHRM1—lung—acquired immunodeficiency syndrome	0.000208	0.0471	CbGeAlD
Trihexyphenidyl—CHRM3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000207	0.00161	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000207	0.00161	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000207	0.00161	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000206	0.0016	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000205	0.00159	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000205	0.00159	CbGpPWpGaD
Trihexyphenidyl—CHRM2—central nervous system—acquired immunodeficiency syndrome	0.000204	0.0461	CbGeAlD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000204	0.00158	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000204	0.00158	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000203	0.00158	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000203	0.00158	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000201	0.00156	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000201	0.00156	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.0002	0.00155	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000198	0.00154	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000197	0.00153	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000197	0.00153	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000196	0.00152	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000194	0.00151	CbGpPWpGaD
Trihexyphenidyl—CHRM1—nervous system—acquired immunodeficiency syndrome	0.000193	0.0436	CbGeAlD
Trihexyphenidyl—CHRM4—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000191	0.00148	CbGpPWpGaD
Trihexyphenidyl—CHRM2—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	0.00019	0.00147	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000188	0.00146	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000188	0.00146	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000188	0.00146	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000186	0.00144	CbGpPWpGaD
Trihexyphenidyl—CHRM1—central nervous system—acquired immunodeficiency syndrome	0.000186	0.042	CbGeAlD
Trihexyphenidyl—CHRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000185	0.00144	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000185	0.00144	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000184	0.00143	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000184	0.00143	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000183	0.00142	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000183	0.00142	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000183	0.00142	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.00018	0.0014	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000172	0.00134	CbGpPWpGaD
Trihexyphenidyl—CHRM3—nervous system—acquired immunodeficiency syndrome	0.000172	0.039	CbGeAlD
Trihexyphenidyl—CHRM3—central nervous system—acquired immunodeficiency syndrome	0.000166	0.0376	CbGeAlD
Trihexyphenidyl—CHRM5—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000165	0.00128	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000162	0.00126	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000162	0.00126	CbGpPWpGaD
Trihexyphenidyl—CHRM2—brain—acquired immunodeficiency syndrome	0.000162	0.0366	CbGeAlD
Trihexyphenidyl—CHRM1—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	0.000157	0.00122	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000155	0.00121	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000155	0.00121	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000155	0.0012	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000155	0.0012	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000153	0.00119	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000153	0.00119	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000152	0.00118	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000151	0.00117	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	0.000149	0.00116	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	0.000148	0.00115	CbGpPWpGaD
Trihexyphenidyl—CHRM1—brain—acquired immunodeficiency syndrome	0.000147	0.0333	CbGeAlD
Trihexyphenidyl—CHRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000141	0.00109	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.00014	0.00109	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.00014	0.00108	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000139	0.00108	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000139	0.00108	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000139	0.00108	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000138	0.00107	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000138	0.00107	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000137	0.00106	CbGpPWpGaD
Trihexyphenidyl—CHRM3—brain—acquired immunodeficiency syndrome	0.000132	0.0298	CbGeAlD
Trihexyphenidyl—CHRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000129	0.000998	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000128	0.000995	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000127	0.000985	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000127	0.000985	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000126	0.000981	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000125	0.000972	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000123	0.000957	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000122	0.000943	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.00012	0.000929	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000118	0.000917	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000116	0.000903	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000116	0.000903	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000116	0.0009	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000115	0.000891	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000115	0.00089	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000111	0.000863	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000109	0.000849	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000109	0.000849	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000109	0.000846	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000109	0.000846	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000109	0.000844	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000108	0.000838	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000108	0.000838	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000106	0.000826	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000104	0.000808	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.32e-05	0.000646	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.29e-05	0.000644	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.21e-05	0.000637	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.19e-05	0.000636	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.17e-05	0.000634	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.09e-05	0.000628	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.07e-05	0.000626	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.05e-05	0.000624	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.97e-05	0.000618	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.49e-05	0.000582	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.47e-05	0.00058	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.4e-05	0.000574	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.33e-05	0.000569	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.31e-05	0.000567	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.24e-05	0.000562	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.42e-05	0.000498	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.39e-05	0.000496	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—ALB—acquired immunodeficiency syndrome	6.37e-05	0.000494	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.15e-05	0.000477	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.12e-05	0.000475	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.33e-05	0.000336	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.32e-05	0.000335	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.31e-05	0.000334	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.29e-05	0.000333	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.27e-05	0.000332	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.25e-05	0.00033	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.77e-05	0.000293	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.61e-05	0.000281	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.54e-05	0.000198	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.54e-05	0.000197	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.51e-05	0.000195	CbGpPWpGaD
